EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS
Imidazopyridine amine telacebec (Q203)
TARGET PROTEIN
respiratory terminal oxidase cytochrome bc1:aa3
MECHANISM OF ACTION
Bactericidal activity
DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)
Investigational
MODE OF ADMINISTRATION
Oral
LINK TO PUBMED
https://pubmed.ncbi.nlm.nih.gov/32866170/
EXTERNAL LINKS
PubChem Compound 69402235
REFERENCE
Chauffour, A., Robert, J., Veziris, N., Aubry, A., Pethe, K., & Jarlier, V. (2020). Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. PLoS Neglected Tropical Diseases, 14(8), 1?12. https://doi.org/10.1371/JOURNAL.PNTD.0007857